The first FDA-approved generic monensin – available to U.S. beef, dairy, and goat producers as Monovet®90 from global animal health company Huvepharma® – has now also received FDA approval for combination use with other drug feed additive products in the manufacture of Type B and C medicated feeds.
Monovet® 90, the generic equivalent to Rumensin® 90, is an ionophore that alters rumen fermentation patterns to increase feed efficiency, particularly among feedlot cattle, and to improve body weight gain of cattle on pasture. The combination approvals allow Monovet® 90 to be used with other feed additives commonly fed to feedlot cattle, such as tylosin, ractopamine, and melengestrol. For the list of current medicated feed combinations approved with Monovet® 90, visit Huvepharma's Blue Bird combinations here.
“By bringing the first generic monensin product in the marketplace, Huvepharma offers livestock producers a new cost-effective choice, while providing the same benefits of dosage, chemical identity, potency, quality, safety, and route of administration,” says Glen Wilkinson, president of Huvepharma US.
Wilkinson reports that Huvepharma has a vertically integrated infrastructure in fermentation production which facilitates their core strength in manufacturing medicated feed additives and other critical products for the animal food producing industry. “Monovet® 90 is an example of Huvepharma’s commitment to bringing effective and essential choices to the U.S. cattle industry,” Wilkinson says.
Huvepharma has been active in the US animal health market since its inception in 2005 providing products for poultry, swine and cattle markets. The company received FDA approval for Monovet® 90 in the U.S. in July 2019, which follows a generic approval for Tylan® sold as Tylovet® (tylosin phosphate).
With the introduction of Monovet® 90 for the U.S. market, Huvepharma will continue to focus on building close partnerships with livestock customers, offering high quality products and unparalleled customer service.
Building on its 60-year history, Huvepharma has focused on becoming a fully-integrated company which includes research and development, production, regulatory activity, sales and marketing. The company today ranks 10th among the largest veterinary pharmaceutical companies, and Huvepharma operates three modern and multipurpose fermentation facilities that manufacture active substances, nutritional supplements, enzymes, probiotics and ready medicinal formulations. In addition, the company has just completed an extensive expansion project that increases production capacity 30% thereby insuring consistent supply of the full portfolio of products.
For more information, please contact your Huvepharma sales representative and/or Huvepharma’s Customer Service team at 877-994-4883.
IMPORTANT SAFETY INFORMATION: MONOVET® 90 (monensin Type A medicated article): Not for Human Use. Do not allow horses or other equines access to feeds containing monensin. Ingestion of monensin by horses has been fatal. Consumption by unapproved species may result in toxic reactions and even fatalities. A withdrawal time has not been established for pre-ruminating calves. Do not use in calves to be processed for veal. When mixing and handling Monovet 90, use protective clothing, impervious gloves and a dust mask. Operators should wash thoroughly with soap and water after handling. If accidental eye contact occurs, immediately rinse with water. To report adverse effects, access medical information, or obtain additional product information, call 1-877-426-7765. View product label here.